Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFINITY: Guselkumab and Golimumab Combination in Psoriatic Arthritis
NCT05071664Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab and Golimumab with Guselkumab and Placebo (2 arms). Primary endpoint: Minimal Disease Activity at 24 weeks. Started Oct 2021; status: completed.
02
Drugs
guselkumabgolimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05071664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071664.